Day Pitney remains committed to providing quality legal counsel, while protecting our clients and employees, and transforming our communities into more just, equal and equitable spaces. For more information, please visit our COVID-19 Resource Center | Racial Justice and Equity Task Force.

Insights

Publications Events Blogs

HHS Eases Prescribing Requirements for Opioid Addiction Medication

Publisher: Day Pitney Cybersecurity, Health and Technology (C.H.A.T.) Newsletter
June 1, 2021
Day Pitney Author(s) Alexandra MacKenzie Pearsall

While opioid overdoses continue to increase during the pandemic, the U.S. Department of Health and Human Services announced that it is easing rules related to the prescription of specific Schedule III, IV and V medications, including the opioid-dependence drug buprenorphine.

Under the new Practice Guidelines released last month, physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives, who are state-licensed and registered with the Drug Enforcement Administration to prescribe controlled substances, will be allowed to prescribe buprenorphine for opioid use disorder (OUD) without going through the previously mandated training course and waiver requirement.

In response to the barriers imposed by the prior training and waiver requirement, this exemption allows eligible practitioners to treat up to 30 patients with OUD using buprenorphine and without having to make certain training-related certifications, such as certifying as to their capacity to provide counseling and ancillary services.

Notably, providers are still required to submit an application designated as a "Notice of Intent" in order to prescribe buprenorphine for the treatment of OUD. Further, this exemption does not apply to the use of Schedule II medications, such as methadone. However, removing most of the administrative hurdles should increase the number of eligible providers to prescribe buprenorphine for OUD and help address the continuing addiction and overdose crisis in the United States.


For more Day Pitney alerts and articles related to the impact of COVID-19, as well as information from other reliable sources, please visit our COVID-19 Resource Center.

COVID-19 DISCLAIMER: As you are aware, as a result of the COVID-19 pandemic, things are changing quickly and the effect, enforceability and interpretation of laws may be affected by future events. The material set forth in this document is not an unequivocal statement of law, but instead represents our best interpretation of where things stand as of the date of first publication. We have not attempted to address the potential impacts of all local, state and federal orders that may have been issued in response to the COVID-19 pandemic.




Would you like to receive our Day Pitney C.H.A.T. Newsletter? Sign up here.


Recommended
Related Professionals
Parsippany, NJ
T: (973) 966 8138
Boston, MA
T: (617) 345 4872
Hartford, CT
T: (860) 275 0168
Stamford, CT
T: (203) 977 7418
Hartford, CT
New Haven, CT
T: (860) 275 0294
Stamford, CT
T: (203) 977 7368
Parsippany, NJ
T: (973) 966 8115
New York, NY
T: (212) 297 2477
Parsippany, NJ
T: (973) 966 8041
Washington, DC
T: (202) 218 3904
Hartford, CT
T: (860) 275 0309
Parsippany, NJ
T: (973) 966 8154